ReviewFrontiers in nutrition2026
Nutrients and bioactive compounds in polycystic ovary syndrome: updated insights into effects and underlying mechanisms.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Weight Reduction via Lifestyle Intervention Improves Androgen Levels and Glucose Metabolism in Women of Reproductive Age with Hyperandrogenism: A Real-World Observational Study.Journal of clinical medicine · 2026Article
- Gut microbiota in PCOS: key microbial changes, potential mechanisms and clinical applications.Journal of translational medicine · 2026Review
- Algae-Derived Bioactives Reprogram the Gut-SIRT1-Kisspeptin Axis in Polycystic Ovary Syndrome.Marine drugs · 2026Review
- Decoding the gut-adipose-ovary axis in polycystic ovary syndrome: from metabolic dysregulation to oncological risk modulation.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorders affecting women of reproductive age. Its complex and heterogeneous clinical presentation has led international evidence-based guidelines to prioritize management strategies aimed at symptom control rather than cure, highlighting the need for novel therapeutic approaches. Women with PCOS frequently exhibit deficiencies in various vitamins and minerals, which are closely associated with the syndrome's characteristic insulin resistance (IR) and endocrine disturbances. Consequently, nutritional supplementation may provide significant adjunctive benefits to conventional therapies. Accumulating evidence indicates that specific vitamins (e.g., E, K, D, B-8, B-9, B-12), minerals (e.g., selenium, chromium, zinc, calcium, magnesium), and other bioactive compounds (e.g., melatonin,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.